Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2010114215) COMPOSITION FOR PREVENTING OR TREATING OBESITY, DYSLIPIDEMIA, FATTY LIVER OR INSULIN RESISTANCE SYNDROME, COMPRISING CAMPHOR AS AN ACTIVE INGREDIENT
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2010/114215 International Application No.: PCT/KR2009/007904
Publication Date: 07.10.2010 International Filing Date: 29.12.2009
IPC:
A61K 31/122 (2006.01) ,A61P 3/04 (2006.01) ,A61P 3/10 (2006.01) ,A23L 1/30 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
12
Ketones
122
having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
04
Anorexiants; Antiobesity agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
08
for glucose homeostasis
10
for hyperglycaemia, e.g. antidiabetics
A HUMAN NECESSITIES
23
FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
L
FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D91; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
1
Foods or foodstuffs; Their preparation or treatment
29
Modifying nutritive qualities of foods; Dietetic products
30
containing additives
Applicants:
박태선 PARK, Taesun [KR/KR]; KR (UsOnly)
연세대학교 산학협력단 INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY [KR/KR]; 서울특별시 서대문구 신촌동 134 연세대학교 Yonsei Univ. 134 Sinchon-dong, Seodaemun-gu Seoul 120-749, KR (AllExceptUS)
Inventors:
박태선 PARK, Taesun; KR
Agent:
양부현 YANG, Boo-Hyun; 서울특별시 관악구 인헌동 1659-2 청동빌딩 301호 Suite 301 Chungdong Building 1659-2 Inhundong, Gwanak-gu Seoul 151-832, KR
Priority Data:
10-2009-002803001.04.2009KR
Title (EN) COMPOSITION FOR PREVENTING OR TREATING OBESITY, DYSLIPIDEMIA, FATTY LIVER OR INSULIN RESISTANCE SYNDROME, COMPRISING CAMPHOR AS AN ACTIVE INGREDIENT
(FR) COMPOSITION DE PREVENTION OU DE TRAITEMENT DE L'OBESITE, DE LA DYSLIPIDEMIE, DE LA STEATOSE HEPATIQUE OU DU SYNDROME DE RESISTANCE A L'INSULINE, CONTENANT DU CAMPHRE COMME PRINCIPE ACTIF
(KO) 캠포를 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물
Abstract:
(EN) The present invention relates to a composition for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome, comprising camphor as an active ingredient. The composition of the present invention, comprising camphor as an active ingredient, inhibits adipocyte differentiation, decreases body fat and abdominal fat, and lowers total cholesterol levels and triglyceride in plasma and triglyceride in the liver, and thus exhibits an activity of preventing or treating obesity, hyperlipidemia or fatty liver. In addition, the composition of the present invention significantly decreases fasting blood sugar and blood insulin levels, to thereby improve insulin resistance and metabolic diseases closely involved in insulin resistance. Further, the composition of the present invention significantly decreases the expression of nuclear transcription factors (C/EBPα and PPARγ2) which play a key role in adipogenesis in the visceral adipose tissue, or target genes thereof, to thereby decrease abdominal fat. The composition significantly decreases the expression of cytokine (TNF-α or IL-6) which causes inflammatory activation, to thereby improve chronic inflammatory activation induced by obesity in visceral adipose tissue. The composition increases the expression of the UCP (UCP1 or UCP3) genes which adjust thermogenesis in the body, to thereby improve the inhibition of thermogenesis induced by obesity in visceral adipose tissue.
(FR) L'invention concerne une composition de prévention ou de traitement de l'obésité, de la dyslipidémie, de la stéatose hépatique ou du syndrome de résistance à l'insuline, contenant du camphre comme principe actif. La composition selon l'invention inhibe la différenciation des adipocytes, réduit la graisse corporelle et la graisse abdominale et réduit les taux de cholestérol total et les triglycérides dans le plasma et dans le foie. Ainsi, la composition présente une activité de prévention ou de traitement de l'obésité, de l'hyperlipémie ou de la stéatose hépatique. En outre, la composition selon l'invention réduit de façon significative les taux de glycémie à jeun et d'insuline dans le sang, ce qui améliore la résistance à l'insuline et les maladies métaboliques étroitement impliquées dans la résistance à l'insuline. Cette composition réduit également de façon significative l'expression de facteurs de transcription nucléaire (C/EBPα et PPARγ2) jouant un rôle majeur dans l'adipogenèse dans le tissu adipeux viscéral, ou de gènes cibles de celui-ci, ce qui diminue la graisse abdominale. Cette composition réduit de façon significative l'expression de cytokines (TNF-α ou IL-6) qui causent l'activation inflammatoire, ce qui améliore l'activation inflammatoire chronique induite par l'obésité dans le tissu adipeux viscéral. La composition selon l'invention augmente l'expression des gènes UCP (UCP1 ou UCP3) qui régulent la thermogenèse dans le corps, ce qui améliore l'inhibition de la thermogenèse induite par l'obésité dans le tissu adipeux viscéral.
(KO) 본 발명은 캠포를 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물에 관한 것이다. 본 발명의 캠포를 유효성분으로 포함하는 조성물은 지방세포 분화의 억제, 체지방량의 감소, 내장 지방량의 감소, 총콜레스테롤 농도의 감소, 혈장 중성지방 및 간조직 중성지방의 감소를 초래하여, 궁극적으로 비만, 고지혈증 또는 지방간의 예방 또는 치료 활성을 나타낸다. 또한, 본 발명의 조성물은 공복시 혈당 및 혈중 인슐린 농도의 유의한 감소를 초래하여 인슐린 저항성을 개선하는 효과 및 이와 밀접하게 관련된 대사질환을 개선하는 효능도 발휘한다. 또한, 본 발명의 조성물은 내장지방 조직에서 지방조직의 생성에 중추적 역할을 하는 핵전사 인자(C/EBPα와 PPARγ2) 또는 이의 타겟 유전자(aP2)의 발현을 유의적으로 감소시켜 내장 지방량 억제 효과를 가지고, 염증을 활성화시키는 사이토카인(TNF-α 또는 IL-6)의 발현을 유의적으로 감소시켜 내장지방조직에서 비만으로 인해 유도된 만성적 염증활성화의 개선 효과를 나타내며, 생체내 열발생을 조절하는 UCPs(UCP1 또는 UCP3) 유전자 발현을 증가시킴으로써, 내장지방조직에서 비만으로 인해 유도된 열 발생 저해현상의 개선 효과를 나
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)